GERN
Geron Corp
NASDAQ · Biotechnology
$1.53
+0.07 (+4.79%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 76.09M | 153.95M | 141.15M | 142.49M |
| Net Income | -172,483,588 | -36,660,557 | -32,364,939 | -40,158,948 |
| EPS | — | — | — | — |
| Profit Margin | -226.7% | -23.8% | -22.9% | -28.2% |
| Rev Growth | +281.2% | +15.1% | +6.9% | +15.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 226.89M | 158.35M | 202.35M | 170.15M |
| Total Equity | 261.45M | 381.18M | 345.34M | 407.50M |
| D/E Ratio | 0.87 | 0.42 | 0.59 | 0.42 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -173,058,107 | -44,322,691 | -40,350,825 | -39,303,619 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 | -39,999,532 |